What are the IDSA recommendations for the management of herpes zoster (shingles) in immunocompromised patients?

Updated: Feb 11, 2021
  • Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print

In its 2014 update of practice guidelines for the diagnosis and management of skin and soft tissue infections, the Infectious Disease Society of America (IDSA) offered recommendations for management in immunocompromised patients. Recommendations include the following [139] :

  • The treatment of choice is high-dose intravenous acyclovir for immunocompromised patients.

  • Oral acyclovir, famciclovir, and valacyclovir is recommended for mild cases in patients with transplant immune suppression or for patients who have shown a clinical response to intravenous acyclovir.

  • Recipients of bone marrow transplants should take oral acyclovir or valacyclovir during the first year for prevention of herpes zoster.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!